A Phase 3 interventional study of Oxycodone hydrochloride controlled-release tablets in Pain, sponsored by Purdue Pharma LP. Completed at 14 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-09-09.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.
Among the 50 studies testing oxycodone in Pain, this one is the 40th largest by enrollment, is one of 2 that started in 2011, is one of 10 in phase 3, and was the 11th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:
Kafrelsheikh University · Sites in Egypt
Ages 18–65
University of Florida · Sites in United States
Ages 45–85 · Healthy volunteers
University of Florida · Sites in United States
Ages 21–45 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 67 across the 50 interventional studies. Of the 37 that completed or were terminated, 13 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Purdue Pharma LP, one of the names counted as Knoa Pharma. Under that name alone:
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
13 studies in Pain by Knoa Pharma: none open now, none under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 13 studies in Pain by Knoa Pharma, this one is the 12th largest by enrollment, is one of 5 that started in 2011, is one of 7 in phase 3, and was the 5th registered.
Knoa Pharma’s Pain studies by the year they started, since 2001.
3 of the studies testing oxycodone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05761860University of FloridaThe Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults | 2026-12 |
| NCT04218409University of FloridaOpioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | 2026-12-31 |
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies testing oxycodone in Pain, from their registry updates:
Among Knoa Pharma’s 13 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged 6 to 17 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy who completed the 4 -week treatment period in OTR3001.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Other protocol specific inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxycodone hydrochloride controlled-release tablets
Drug: Oxycodone hydrochloride controlled-release tablets
Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
Also known as: OxyContin
The Number of Participants With Adverse Events as a Measure of Safety.
Safety assessments included adverse events (AEs), vital sign measurements, clinical laboratory test results, and somnolence (University of Michigan Sedation Scale \[UMSS\]). Safety variables were summarized descriptively within age group for the extension safety population.
Time frame: Up to 6 months (during the study) and 7-10 days poststudy (safety follow-up assessment).
First Patient First Visit: 05-January-2012; Last Patient Last Visit: 09-December-2013. The study was conducted at 14 medical/research sites in the United States and Israel.
| Milestone | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Started | 9 | 14 |
| Completed | 9 | 12 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Safety assessments included adverse events (AEs), vital sign measurements, clinical laboratory test results, and somnolence (University of Michigan Sedation Scale \[UMSS\]). Safety variables were summarized descriptively within age group for the extension safety population.
| participants | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Serious adverse events | 3 | 2 |
| All other adverse events in ≥ 5% of patients | 8 | 8 |
Collected over Adverse events (AEs) were reported from start of study participation through the period beyond study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 6 to < 12 Years | — | 3/9 (33.3%) | 8/9 (88.9%) |
| ≥ 12 to ≤ 16 Years | — | 2/14 (14.3%) | 8/14 (57.1%) |
| Event | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Sickle cell anaemia with crisisCongenital, familial and genetic disorders | 1/9 | 1/14 |
| ConstipationGastrointestinal disorders | 1/9 | 0/14 |
| PyrexiaGeneral disorders | 1/9 | 0/14 |
| VomitingGastrointestinal disorders | 0/9 | 1/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 1/14 |
| HeadacheNervous system disorders | 0/9 | 1/14 |
| Event | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| PyrexiaGeneral disorders | 3/9 | 2/14 |
| VomitingGastrointestinal disorders | 2/9 | 2/14 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/9 | 0/14 |
| AnaemiaBlood and lymphatic system disorders | 1/9 | 0/14 |
| LymphadenopathyBlood and lymphatic system disorders | 1/9 | 0/14 |
| External ear painEar and labyrinth disorders | 1/9 | 0/14 |
| ConjunctivitisEye disorders | 1/9 | 0/14 |
| Eye painEye disorders | 1/9 | 0/14 |
| MydriasisEye disorders | 1/9 | 0/14 |
| ConstipationGastrointestinal disorders | 1/9 | 1/14 |
The extension safety population was the group of patients who received at least 1 dose of study drug during the Extension Study.
| Age, Continuous(years) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| Mean | 9.9 ± 1.76 | 14.3 ± 1.49 | 12.6 ± 2.69 |
| Sex: Female, Male(Participants) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 3 | 7 | 10 |
| Race/Ethnicity, Customized(participants) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| White | 6 | 10 | 16 |
| Black or African American | 3 | 4 | 7 |
The record gives a start of Oct 2011, a primary completion of Dec 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone